Progyny (NASDAQ:PGNY) Shares Unloaded Rep. Josh Gottheimer

Representative Josh Gottheimer (D-New Jersey) recently sold shares of Progyny, Inc. (NASDAQ:PGNY). In a filing disclosed on January 14th, the Representative disclosed that they had sold between $1,001 and $15,000 in Progyny stock on December 6th. The trade occurred in the Representative’s “MORGAN STANLEY – SELECT UMA ACCOUNT # 1” account.

Representative Josh Gottheimer also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of Block (NYSE:SQ) on 12/30/2024.
• Purchased $1,001 – $15,000 in shares of The Goldman Sachs Group (NYSE:GS) on 12/30/2024.
• Sold $1,001 – $15,000 in shares of Ambev (NYSE:ABEV) on 12/27/2024.
• Sold $1,001 – $15,000 in shares of Grupo Financiero Banorte (OTCMKTS:GBOOY) on 12/27/2024.
• Sold $1,001 – $15,000 in shares of Cadre (NYSE:CDRE) on 12/27/2024.
• Sold $1,001 – $15,000 in shares of Coloplast A/S (OTCMKTS:CLPBY) on 12/27/2024.
• Sold $1,001 – $15,000 in shares of Intuitive Surgical (NASDAQ:ISRG) on 12/23/2024.
• Sold $1,001 – $15,000 in shares of Trane Technologies (NYSE:TT) on 12/23/2024.
• Purchased $1,001 – $15,000 in shares of Walmart (NYSE:WMT) on 12/20/2024.
• Sold $1,001 – $15,000 in shares of NVIDIA (NASDAQ:NVDA) on 12/19/2024.

Progyny Trading Down 0.6 %

Shares of NASDAQ:PGNY opened at $20.62 on Friday. The firm has a 50 day moving average of $15.92 and a 200-day moving average of $19.69. The stock has a market capitalization of $1.76 billion, a PE ratio of 35.55, a PEG ratio of 1.95 and a beta of 1.31. Progyny, Inc. has a 12 month low of $13.39 and a 12 month high of $42.08.

Progyny (NASDAQ:PGNY) last released its quarterly earnings data on Tuesday, November 12th. The company reported $0.11 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.37 by ($0.26). The company had revenue of $286.63 million for the quarter, compared to analyst estimates of $296.85 million. Progyny had a return on equity of 11.36% and a net margin of 5.03%. Progyny’s revenue for the quarter was up 2.0% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.16 earnings per share. On average, research analysts predict that Progyny, Inc. will post 0.59 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Ballentine Partners LLC acquired a new position in Progyny during the fourth quarter worth $187,000. Leibman Financial Services Inc. raised its holdings in shares of Progyny by 100.7% in the fourth quarter. Leibman Financial Services Inc. now owns 63,509 shares of the company’s stock valued at $1,096,000 after purchasing an additional 31,872 shares during the last quarter. Nordea Investment Management AB raised its holdings in shares of Progyny by 5.8% in the fourth quarter. Nordea Investment Management AB now owns 185,042 shares of the company’s stock valued at $3,175,000 after purchasing an additional 10,203 shares during the last quarter. Central Pacific Bank Trust Division raised its holdings in shares of Progyny by 89.8% in the fourth quarter. Central Pacific Bank Trust Division now owns 13,250 shares of the company’s stock valued at $229,000 after purchasing an additional 6,270 shares during the last quarter. Finally, GAMMA Investing LLC raised its holdings in shares of Progyny by 341.4% in the fourth quarter. GAMMA Investing LLC now owns 1,611 shares of the company’s stock valued at $28,000 after purchasing an additional 1,246 shares during the last quarter. Institutional investors and hedge funds own 94.93% of the company’s stock.

Insider Activity

In other news, Chairman David J. Schlanger bought 150,000 shares of the stock in a transaction dated Thursday, December 26th. The stock was bought at an average price of $14.68 per share, for a total transaction of $2,202,000.00. Following the completion of the acquisition, the chairman now directly owns 228,269 shares in the company, valued at approximately $3,350,988.92. This trade represents a 191.65 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Peter Anevski acquired 209,500 shares of the firm’s stock in a transaction that occurred on Monday, December 23rd. The shares were bought at an average price of $14.48 per share, with a total value of $3,033,560.00. Following the acquisition, the chief executive officer now directly owns 441,463 shares of the company’s stock, valued at $6,392,384.24. The trade was a 90.32 % increase in their position. The disclosure for this purchase can be found here. 12.30% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

PGNY has been the subject of several recent research reports. Cantor Fitzgerald restated an “overweight” rating and issued a $25.00 price target on shares of Progyny in a research report on Tuesday, October 1st. Canaccord Genuity Group decreased their price target on shares of Progyny from $18.00 to $17.00 and set a “hold” rating for the company in a research report on Wednesday, November 13th. JPMorgan Chase & Co. restated a “neutral” rating and issued a $17.00 price target (down from $22.00) on shares of Progyny in a research report on Monday, December 2nd. Bank of America reduced their price objective on shares of Progyny from $22.00 to $21.00 and set a “buy” rating on the stock in a research note on Wednesday, November 13th. Finally, Barclays reduced their price objective on shares of Progyny from $30.00 to $17.00 and set an “overweight” rating on the stock in a research note on Thursday, November 14th. Nine equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $25.00.

About Representative Gottheimer

Josh Gottheimer (Democratic Party) is a member of the U.S. House, representing New Jersey’s 5th Congressional District. He assumed office on January 3, 2017. His current term ends on January 3, 2025. Gottheimer (Democratic Party) is running for re-election to the U.S. House to represent New Jersey’s 5th Congressional District. He declared candidacy for the 2024 election. Gottheimer was first elected to the House in 2016. Prior to his election, Gottheimer worked for Microsoft, the Federal Communications Commission, and for the administration of President Bill Clinton (D). Click here for more information about Gottheimer’s career. Gottheimer serves on the House Financial Services Committee, where is a member of three subcommittees. For more on Gottheimer’s committee assignments, click here. Gottheimer became a co-chair of the Problem Solvers Caucus in February 2017. Gottheimer attended the University of Pennsylvania for his undergraduate degree. He became a Thouron Fellow at Oxford and attended Harvard Law School. Gottheimer worked as a speech writer under former President Bill Clinton (D), assisting with two State of the Union addresses, among other projects. Before running for Congress, he worked for Microsoft as a general manager for corporate strategy.

About Progyny

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.